United States relaxes rules for biotech crops
By Erik Stokstad,
Science
| 05. 18. 2020
New regulations focus on traits, not the technology used to create them. An engineered plant won’t be regulated if it contains minor changes that could have been made through traditional breeding.
Photo by Erwan Hesry via Unsplash.com
A major change to U.S. regulation of biotech will exempt some gene-edited plants from government oversight. The new policy, published in the Federal Register today, also calls for automatic approval of variations of established kinds of genetically modified (GM) crops, easing their path to market.
Industry groups are welcoming the new rule, whereas opponents are decrying the reduction of government oversight.
“The main good thing is that it will allow certain aspects of gene editing to move forward,” says Kent Bradford, a plant geneticist at the University of California, Davis. If researchers use gene editing to design a plant that could have been bred conventionally, the new plant will be exempt from regulation. But anything else—such as moving a gene between species or rewiring metabolism—will still require a regulatory review.
The gist of the shift is that the U.S. Department of Agriculture’s (USDA’s) Animal and Plant Health Inspection Service (APHIS) will now focus on new traits themselves rather than the technology used to create them, a change of approach that plant scientists have long...
Related Articles
By Diaa Hadid and Shweta Desai, NPR | 01.29.2026
MUMBRA, India — The afternoon sun shines on the woman in a commuter-town café, highlighting her almond-shaped eyes and pale skin, a look often sought after by couples who need an egg to have a baby.
"I have good eggs,"...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...
By Staff, ScienceDaily | 01.05.2026
Scientists at UNSW Sydney have developed a new form of CRISPR technology that could make gene therapy safer while also resolving a decades-long debate about how genes are switched off. The research shows that small chemical markers attached to DNA
...
Following a long-standing CGS tradition, we present a selection of our favorite Biopolitical Times posts of the past year.
In 2025, we published up to four posts every month, written by 12 authors (staff, consultants and allies), some in collaboration and one simply credited to CGS.
These titles are presented in chronological order, except for three In Memoriam notices, which follow. Many more posts that are worth your time can be found in the archive. Scroll down and “VIEW...